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Objectives: The aim of the study was to assess fertility in patients diagnosed with ectopic pregnancy and treated 
with methotrexate, as well as safety and efficacy of conservative treatment. Also, risk factors of recurrent ectopic 
pregnancies were determined.
Material and methods: The study included 86 female patients with ectopic pregnancy, hospitalized and treated in 
the clinic of Gynecological Endocrinology, UJCM, Cracow, between 2007 and 2011. A total of 73 patients received 
a single dose of M TX in the amount of 50mg/m2 of body surface area. Serum b-hCG concentration was measured 
on days 4 and 7. The treatment was considered successful when b-hCG concentrations dropped to less than
0.2mIU/ml without surgery.
Results: Among 34 patients on follow-up, 8 (23.5%) did not attempt to conceive again, whereas 26 patients 
declared their wish to conceive again. The attempt proved to be successful in case of 16 women (61.53%), and 
they gave birth to healthy children. Average time to pregnancy was 14.9 months (SD±10.9). The first pregnancy 
occurred after 6 months and the last after 35 months. No congenital birth defects were found in the newborns. 
Conclusions: Systemic, conservative treatment with methotrexate is an effective and safe way of managing ectopic 
pregnancy, even in cases with higher b-hCG concentrations. Most patients can be successfully treated without 
surgery, thus they may even be treated in outpatient settings. High fertility can be maintained and is independent of 
the skills o f the operators and access to laparoscopic techniques. Conservative treatment does not increase the risk 
of recurrent ectopic pregnancy but should be offered in wards that provide 24-hour surgical care.
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Streszczenie
Cel pracy: Badanie miało na celu ocenę płodności pacjentek ze zdiagnozowaną ciążą pozamaciczną leczonych 
metotreksatem, skuteczność i bezpieczeństwo leczenia zachowawczego oraz poszukiwanie czynników ryzyka 
powtórnej ciąży pozamacicznej.
Materiał i metody: 86 pacjentek ze zdiagnozowaną ciążą pozamaciczną było objętych leczeniem w Klinice 
Endokrynologii Ginekologicznej UJCM  w Krakowie od 2007 do 2011 roku. Po zakwalifikowaniu u 73 pacjentek 
zastosowano terapię pojedynczej dawki metotreksatu w ilości 50 mg/m2 powierzchni ciała. Kolejno oceniano 
stężenia b-hCG w surowicy krwi w dniu czwartym i siódmym terapii. Za sukces terapeutyczny uznawano obniżenie 
wartości b-hCG poniżej 0,2 mIU/ml bez konieczności wykonania zabiegu operacyjnego.
Wyniki: Pośród 34 pacjentek z  przebywających w opiece przyklinicznej, 8 (23,5%) nie zdecydowało się na 
kolejną ciążę. 26 pacjentek zdeklarowało plany reprodukcyjne, 16 (61,53%) z  nich urodziło zdrowe dzieci. Średni 
czas do uzyskania ciąży wynosił 14,9 (SD 10,9) miesiąca. Pierwsza ciąża wystąpiła po 6 miesiącach a ostatnia 
obserwowana po 35 miesiącach. Nie zaobserwowano żadnych wad wrodzonych u urodzonych dzieci.
Wnioski: Systemowe leczenie zachowawcze metotreksatem jest terapią skuteczną i bezpieczną nawet przy 
wyższych wartościach b-hCG niż 3500 mIU/ml. Umożliwia wyleczenie większości pacjentek bez konieczności 
wykonywania zabiegu operacyjnego, nawet w trybie ambulatoryjnym. Pozwala na utrzymanie wysokiej płodności 
niezależnie od umiejętności operatora i dostępności technik laparoskopowych. Leczenie zachowawcze nie 
zwiększa ryzyka rozwoju ponownie ciąży pozamacicznej.
Słowa kluczowe: ciąża ektopowa metotreksat płodność leczenie zachowawcze /
Introduction
The frequency of ectopic pregnancies has been on the rise. 
The Center fo r  Disease Control and Prevention (CDC) estimated 
that in 1992, 1.97% of all pregnancies were ectopic. Currently, 
CDC reports the percentage to have risen to 2.07-2.43% [1]. 
Furthermore, they report a 6-fold increase in ectopic pregnancies 
(from 17 800 cases in 1970 to 108 000 cases in 1992), related to 
widespread access to assisted reproductive technologies (ART) 
[2], greater prevalence of sexually transmitted diseases, and 
increased incidence of pelvic inflammatory diseases (PID) [2, 3] 
-  especially due to Chlamydia trachomatis infections [4, 5, 6, 7].
Until the end of the 1980s, laparoscopy has remained the 
main diagnostic tool for ectopic pregnancy. In the last decade, 
the development o f ultrasonography has allowed improvements 
in the diagnosis with sufficient sensitivity and specificity of 
incorrectly implanted embryos. The sensitivity and specificity of 
a single transvaginal ultrasonography test (TVS) are 74% (95% 
CI:65.1 -  81.6) and 99.9% (95% CI:99.8 -  100), respectively 
[8]. It is estimated that 60% of ectopic pregnancies appear as a 
heterogeneous mass adjacent to the ovary -  a ‘blob sign’, 20% 
as an area with a hyperechogenic ring -  a ‘bagel sign ’, and 13% 
as a gestational sac containing a fetal pole with present or absent 
heart activity. TVS is the gold standard in the early diagnosis of 
any type of ectopic pregnancy, whereas laparoscopy only has 
a role in case of treatment intervention [9]. There also exists a 
small group of women with a positive pregnancy test and an 
uncharacteristic image in TVS testing, described in the literature 
as PUL (Pregnancy of Unknown Location).
The second essential factor in diagnosing an ectopic 
pregnancy is the concentration of human chorionic gonadotropin 
(hCG) in the blood serum. In the 1960s, there was an improvement 
in the method used to determine the b-hCG subunit in urine as 
low as 1000 mIU/ml, which allowed for this method to be used in 
the early diagnosis of ectopic pregnancy [10].
Presently used immunoenzymatic (ELISA) methods can 
show b-hCG levels of 15 mIU/ml in the blood serum within one 
hour. Additionally, in a series of tests, a slower increase in b-hCG 
in the blood serum is observed in cases of ectopic pregnancies, 
compared to the physiological doubling within 48 hours in 
eutopic pregnancies. The risk for an ectopic pregnancy is high 
if the observed increase of the value is less than 66%. The use of 
the diagnostic method of increasing b-hCG levels alone results 
in 13% of ectopic pregnancies being undiagnosed. Moreover, a 
lower than expected rise in b-hCG levels may also be observed 
in 15% of normal pregnancies [11]. Presently, early diagnosis of 
ectopic pregnancy is based on combining the TVS evaluation 
with serum b-hCG concentration.
Since 1849, when the first operation due to intra-abdominal 
hemorrhage caused by an ectopic pregnancy was performed [12], 
laparoscopic techniques have started to replace laparotomy and 
become an essential part o f the treatment. Simultaneously, in 1985, 
Chotiner was the first to report a successful treatment of a fallopian 
tube pregnancy using methotrexate (MTX) [13], beginning 
an era of conservative management. Methotrexate, a folic acid 
antagonist, disrupts proper DNA synthesis, thus inhibiting cell 
proliferation. Trophoblastic tissue is especially sensitive to the 
effect of this cytostatic drug. With regard to its mechanism of 
action, it is important to note strong anti-inflammatory properties 
[14] ofM TX, which may have a positive influence on improving 
fertility in the future. Various schemes of conservative treatment 
are used. Due to high costs o f hospitalization, a benefit was 
demonstrated in patients with conservative MTX treatment in 
a scheme of multiple doses, where b-hCG concentrations were 
<1500 mIU/ml [15]. In contrast to this scheme, application of 
a single dose in the amount o f 50 mg/m2 of body surface area 
contributed to the reduction of treatment costs by shortening 
the duration of hospitalization, which also justifies the use of 
conservative treatment in higher b-hCG concentrations. Special
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attention is given to the fact that the treatment may be used in 
outpatient practices [16]. MTX given locally, both under TVS as 
well as laparoscopic control [14], did not demonstrate signihcant 
differences as compared to intramuscular administration. The 
advantages of systemic administration include simplicity of 
therapy, independence of the skills o f the operator, as well as the 
possibility of treatment in outpatient settings.
A negative effect on fertility due to MTX treatment has not 
been observed [17, 18, 19, 20]. More importantly, no negative 
effect on the ovarian reserve has been noted, either [21]. The 
most common etiology of ectopic pregnancy is considered to 
be the clinical or sub-clinical inflammation of the fallopian 
tubes, possibly leading to irreversible and bilateral damage 
of their function. Consequently, this results in recurrences of 
incorrectly implanted pregnancies or difficulties to conceive 
[22]. Conservative treatment with MTX, due to its strong anti­
inflammatory properties, may positively influence the function of 
the opposite fallopian tube, thus contributing to improving further 
procreation.
The time period of complete excretion of MTX from the 
body is 4 -  6 months [23, 24]. The fact that MTX therapy is safe 
for future offspring is particularly noteworthy. In retrospective 
studies, no differences were demonstrated in the frequencies of 
fetal defects between patients who conceived within 3 months 
(3.6 SD=1.7) into the MTX treatment as compared to those who 
conceived after a longer period of time (23.6 SD=14.7) [25]. The 
risk was equal to that o f the general population.
Objectives
The aims of the study were to evaluate fertility of patients 
diagnosed with an ectopic pregnancy and treated with MTX, to 
assess the safety and efficacy of conservative treatment, and to 
determine the risk factors of recurrent ectopic pregnancies.
Material and methods
A total of 86 female patients diagnosed with an ectopic 
pregnancy were hospitalized and treated in the clinic of 
Gynecological Endocrinology, UJCM, Cracow, between 2007 
and 2011. The diagnosis was established on the basis o f an 
abnormal increase in b-hCG concentrations and ultrasonographic 
(TVS) confirmation of changes in the paraovarian region with 
the aid of the GE Voluson 730 Expert, or on the basis of b-hCG 
> 1000 mIU/ml and absence of a gestational sac in the uterine 
cavity.
Among the 73 patients who were qualified for conservative 
MTX treatment, none of the pregnancies displayed signs of fetal 
cardiac activity or signs of active hemorrhage into the abdominal 
cavity. Excluding criteria were: hemodynamic instability, signs 
of peritonitis, heterotopic pregnancy, contraindications to 
administering methotrexate (e.g. leukopenia, thrombocytopenia, 
elevated liver enzymes, or biochemical indicators of renal 
insufficiency). After obtaining written consent for the proposed 
treatment plan, the patients received a single dose of MTX in 
the amount of 50mg/m2 of body surface area. Subsequently, 
serum b-hCG concentration was measured on days 4 and 7 
after the first dose. Also, blood morphology and liver enzymes 
were monitored. If  a decrease of at least 30% of the maximum 
b-hCG value was observed, the patient was discharged from the 
ward and instructed to monitor b-hCG concentrations weekly at
the outpatient clinic and to undergo TVS testing until complete 
disappearance of b-hCG. After the completion of therapy, OCP 
was recommended for a period of 3 months and telephone contact 
with the primary care physician was ensured. Furthermore, folic 
acid supplementation in prophylactic dosage was added inpatients 
who did as well as did not intend to conceive in the future.
The next dose of MTX was administered to those patients 
in whom b-hCG concentrations decreased by less than 15%, 
remained constant, or increased between days 4 and 7 after 
initiating the first dose. Subsequent doses were administered 
until a satisfactory decrease in serum b-hCG concentration 
was obtained or signs of adverse effects due to the medication 
appeared. The maximal dose of MTX was 200mg throughout 
the course of the treatment and the treatment regimen was in 
compliance with the guidelines for initiating and withdrawing 
the medication. Patients were instructed to attend regular follow- 
up visits at the outpatient clinic 12, 18, 24 and 36 months after 
treatment completion, especially in cases when they wished to 
conceive again.
The treatment was considered successful when b-hCG 
concentrations dropped to less than 0.2mIU/ml after initiating 
conservative therapy without the need of surgical intervention.
In cases of observation loss, i.e. the patient did not appear 
at the outpatient clinic 12, 18, 24 and 36 months after treatment 
completion, telephone contact was made in order to determine 
their procreative status.
Statistical analyses were conducted with STATISTICA 10. 
The Shapiro-Wilk test was used for the analysis of normally 
distribution variables. Means, median, standard deviations, as 
well as minimum and maximum values, were calculated for 
continuous data. The Mann-Whitney test was used for group 
comparisons of continuous variables. The chi-square test for 
independence was used for group comparisons of categorical 
variables./) <0.05 was considered as statistically significant.
Results
A total of 86 patients participated in the study and after 
fulfilling the criteria for initiating and withdrawing MTX, 73 
patients (84.9%) qualified for conservative treatment, 12 patients 
(14%) qualified for the surgical treatment and in 1 patient (1.1%) 
the treatment was observational. Despite conservative treatment, 
intra-abdominal hemorrhage occurred in 6 patients (7%) during 
hospitalization and surgical intervention was required. The fact 
that there was only one case of fallopian tube perforation during 
the surgical intervention is particularly noteworthy.
The average length of hospitalization in patients undergoing 
conservative treatment was 9.7 days (SD±5.2). The average 
concentration of b-hCG upon admission was 3569.8 mlU/ 
ml (SD±4552.9), with a maximum b-hCG concentration of 
4809.3 mIU/ml (SD ±6079.4). Upon discharge, the average 
concentration of b-hCG was 2234.7 mIU/ml (SD±3202.4), 
indicating a decrease of b-hCG by 57.5% (SD±25.1) in relation 
to the maximal values during hospitalization. In the majority 
of patients, intramuscular 150 mg MTX (48.8%) was injected 
in three doses, 50 mg each. The characteristics of the analyzed 
groups in terms of the length of hospitalization, age, BMI, 
obstetric history, b-hCG concentrations, as well as symptoms 
upon admission, are presented in Table I. The decrease ofb-hCG 
to undetectable levels took approximately 45 days.
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T a b le  I.
Age (years) 30.0 ±4.8
BMI (kg/m2) 22.6 ± 3.1
Next pregnancy
First pregnancy 47 54%
Next pregnancy 39 46%
Number of the 
current pregnancy
First 47 54%
Second 22 25.58%
Third 13 15.11%
Fourth 1 1.16%
Fifth 3 3.48%
Number o f prev. D&C
0 75 87.2%
1 9 10.46%
2 1 1.16%
4 1 1.16%
Number o f prev. 
vaginal deliveries
0 71 82.55%
1 15 17.44%
Number o f prev. 
cesarean sections
0 76 88.37%
1 9 10.46%
2 1 1.16%
Number o f prev. 
ectopic pregnancies
0 76 88.37%
1 9 10.46%
2 1 1.16%
Number o f prev. 
abortions
0 67 77.9%
1 15 17.44%
2 2 2.32%
3 1 1.16%
4 1 1.16%
Abdominal pain upon admission 38 44.18%
Vaginal bleeding upon admission 67 77.9%
Free fluid in the abdomen upon 
admission 25 29.06%
Mean time o f hospitalization (days) 9.7 ± 5.2
Mean b-hCG upon admission (mIU/ml) 3569.8 ± 4552.9
Mean b-hCG max (mIU/ml) 4809.3 ± 6079.4
Mean b-hCG on discharge (mIU/ml) 2234.7 ± 3202.4
Mean decrease o f b-hCG on discharge
(%) 57.5 ± 25.1
3  60%
e f
/J
_ f
10 12 14 16 18 20 22 24 26 28 *0 32
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Figure 1.
Information regarding reproductive plans and possible 
pregnancies was obtained from 40 patients during patient follow- 
up visits to the outpatient clinic, as well as through telephone 
contact. Three months into the MTX treatment, 3 patients decided 
to enroll into an in vitro fertilization program and 2 of them gave 
birth to healthy children. These patients were excluded from 
further studies. Surgical procedures were performed in 3 other 
patients during MTX therapy and these patients were not included 
in further studies, either. Among the 34 patients that qualified for 
further statistical analysis, 8 (23.5%) did not attempt to conceive 
again, whereas 26 patients attempted to conceive again and 16 of 
them (61.53%) gave birth to healthy children. The average time 
to pregnancy was 14.9 months (SD±10.9), with the first and the 
last pregnancy occurring after 6 and 35 months, respectively. The 
cumulative pregnancy rate after a 42-month observation period 
post-treatment is illustrated in Figure #1. Not a single case of
congenital birth defects, especially neural tube or cardiac, was 
observed . The average birth weight was 3425g (SD±408.3). A 
recurrence of ectopic pregnancy was not observed in the study 
population. The characteristics of patients who gave birth as well 
as those who, despite expectations, did not conceive are presented 
in Table II.
Discussion
Methotrexate remains to be the most commonly used, as well 
as the most effective, medication in conservative management of 
ectopic pregnancy. This antagonist o f folic acid disrupts DNA 
synthesis and inhibits cell proliferation. The rapidly dividing 
trophoblastic tissue is especially sensitive to its effects. MTX 
effect on other tissues strongly depends on the dose of the drug. The 
most commonly encountered adverse effects of MTX overdose 
include inflammation of the mucosa of the gastrointestinal tract, 
bone marrow suppression, conjunctivitis, hepatotoxicity, and 
photosensitivity. Systemic administration of the medication may 
be used in a variety of schemes. In our study, a single dose of 
50 mg MTX, without additional folic acid supplementation, 
was administered. In cases with insufficient drops of the b-hCG 
concentration, additional doses of MTX were given.
The efficacy of conservative MTX treatment was 93%. 
Noteworthy, the treatment was effective in patients with higher 
b-hCG concentrations (maximal value: 22088 mIU/ml). The 
number of doses of MTX and the total dose administered are 
presented in Table III, respectively. Such a high percentage of 
treatment success encourages physicians to attempt administering
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T a b le  II.
1- pregnant 
2- not pregnant
number of 
patients mean SD min max p value
Hospitalization time (days)
1 15 11.7 4.1 6 18
0.06
2 10 8.4 3.7 4 15
First b-hCG (IU/ml)
1 16 3185.6 2688.7 58 8414
0.12
2 10 1478 1261.6 76 3937
Max b-hCG (IU/ml)
1 16 4404.6 3855.7 58 3425.5
0.06
2 10 1920.4 2194.6 118 1259
b-hCG on discharge (IU/ml)
1 15 2011.9 1638 17 5279
0.08
2 10 1072.4 1715.6 38 5772
Decrease of b-hCG on 
discharge (%)
1 15 55.4 22.9 23.4 96.1
0.85
2 10 52.4 20.3 21.3 87.8
BMI (kg/m2)
1 16 22.4 2.3 19.6 26.2
0.79
2 10 22.8 4.4 18 29.2
age (years)
1 16 28.9 4.6 22 39
0.17
2 10 31.4 4.5 30 40
the medication in outpatient settings, which would significantly 
contribute to reducing hospitalization costs. This course of 
action requires proper training of the medical and nursing staff 
at the outpatient clinic, as well as establishing specific criteria 
regarding administering subsequent MTX doses and recurrent 
hospitalization. It is also necessary to educate patients and their 
families so that they know how to react properly in the case of 
worsening complaints.
Under ideal operating conditions, a cumulative pregnancy 
rate similar to the one found with conservative MTX treatment 
was observed. Such ideal conditions can occur only in case of 
microsurgical reanastomosis of the fallopian tubes after a prior 
tubal ligation, where the cumulative pregnancy rate (including 
ectopic) is 62.5% [26].
In the study population subjected to MTX therapy, ectopic 
pregnancies were not observed. Unfortunately, microsurgeries of 
the fallopian tubes using the laparoscopic technique have a flat 
learning curve, which may result in an insufficiency of highly 
trained staff members, especially during emergency situations.
Fertility evaluation in patients after conservative treatment 
was highly satisfactory. During hospitalization, no statistical 
significance in the amount of the administered MTX was observed 
between patients with an attempted failed conception and patients 
with a successful pregnancy and delivery. Also, there were no 
significant differences between the rate of decrease of the b-hCG 
concentration and hospitalization length -  (Pearson's correlation 
coefficient r=0.802). It is interesting to consider elevated b-hCG 
concentrations on the border o f statistical significance (/=0.06) 
in case of patients that successfully conceived. This may be due 
to greater blood flow in the region of the ectopic pregnancy, thus 
facilitating drug absorption into the target tissue.
T a b le  III.
Dose of 
Methotrexate 
i.m.
number of 
MTX dosages
number of 
patients
percentage of 
patients
50 mg 1 6 7.0%
100 mg 2 19 22.1%
150 mg 3 42 48.8%
200mg 4 6 7.0%
The presence of symptoms upon admission was on the 
border of significance (/=0.06) -  i.e. abdominal pain and vaginal 
bleeding, which was more frequent in patients able to conceive 
spontaneously after the treatment. We suspect that one of the 
main factors in maintaining further fertility is localization of 
the ectopic pregnancy. Severe signs and symptoms may suggest 
an intramural section of the fallopian tube. Although a greater 
intensity of symptoms makes the decision for conservative 
treatment more difficult, MTX treatment remains to be beneficial.
It is worth to mention the emotional trauma which 
accompanies the diagnosis of an ectopic pregnancy. The diagnosis, 
and the following grief, may have an impact on the sexuality of 
the couple. As conservative treatment is more time consuming, 
patients should be offered Tender Loving Care (TLC).
Studies have shown that TLC may have a significant impact 
on the chance of a live birth rate in the next pregnancy [27]. We 
find the perspective of regaining fertility especially important to 
these couples.
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It is also vital to note that MTX therapy is the treatment of 
choice in cases of unique localizations of an ectopic pregnancy, 
such as cervical and uterine scar pregnancies. Finally, in uncertain 
cases effort should be undertaken to avoid ethical consequences 
o f the wrong diagnosis and decision.
Conclusions
Systemic, conservative management with methotrex ate is an 
effective and safe form of treating an ectopic pregnancy, even in 
cases where b-hCG concentrations are greater than 3500 mIU/ 
ml. The majority of patients can be successfully treated without 
surgery, and therefore may even be treated in outpatient settings.
High fertility, independent of the skills of the operators 
and access to laparoscopic techniques, can be maintained. 
Conservative treatment does not increase the risk of developing 
a recurrent ectopic pregnancy. Treatment should be offered in 
wards that provide 24-hour surgical care.
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